Moxifloxacin versus ciprofloxacin plus co-amoxiclav for fever in low-risk neutropoenic patients with cancer
Source: Journal of Clinical Oncology
Area: News
According to the results of a double-blind RCT, monotherapy with once daily oral moxifloxacin is associated with similar efficacy to ciprofloxacin plus co-amoxiclav combination therapy in the treatment of fever in adults with cancer and neutropoenia who are deemed to be at low-risk of complications.
The authors note that prompt empirical antibiotic therapy for fever in patients with neutropenia has become the standard of care; current guidelines recommend oral ciprofloxacin plus co-amoxiclav as the standard regimen for those who are low-risk. The purpose of the current study was to compare the efficacy and safety of moxifloxacin (an extended-spectrum fluoroquinolone) with this oral combination therapy.
The study included 341 patients with cancer, febrile neutropoenia and a low risk of complications, as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score >20. Six patients were subsequently found to be ineligible and two ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Antibiotic Therapy | Avelox | Cancer | Cancer & Oncology | Cipro | Ciprofloxacin | Drugs & Pharmacology | Moxifloxacin | Oral Cancer | Study